{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-017870","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2026-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.350805+00:00","generated_at":"2026-05-16T01:31:10.498314+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Organon Audit Committee completes biosimilar purchase review, finds no improper conduct","bullets":["Audit Committee completed independent review of timing of biosimilar purchases from a supplier in prior years.","Review found no evidence of improper conduct and no adjustments to previously issued financial statements.","Company intends to file its Form 10-K for the year ended December 31, 2025 on time.","No changes required to SEC disclosures related to the transactions reviewed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-017870","json":"https://secwatch.observer/filing/0001104659-26-017870.json","markdown":"https://secwatch.observer/filing/0001104659-26-017870.md","text":"https://secwatch.observer/filing/0001104659-26-017870.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465926017870/0001104659-26-017870-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465926017870/tm266880d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:31:10.498314+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}